{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:10:58Z","timestamp":1784902258457,"version":"3.55.0"},"reference-count":31,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Introduction: A pathological complete response (pCR) to neoadjuvant therapy is what makes organ preservation possible in rectal cancer, so a reliable pre-treatment estimate of the likelihood of pCR would influence management. Prediction research has focused on imaging and artificial intelligence, leaving the clinical models that any unit should be able to apply largely untested beyond their original cohorts. We validated two such models eiyh our own patients, examined whether local refitting helped, and measured how often pCR occurs across the regimens we use. Methods: This was a single-centre cohort of consecutive rectal cancer patients treated with neoadjuvant therapy and resection between 2016 and 2025, drawn from a prospectively maintained registry. pCR was defined as ypT0N0 (no residual invasive tumour in the rectal wall or in the regional lymph nodes on the resection specimen). Two published clinical models (Wang and colleagues; Tan and colleagues) were applied using their original coefficients and assessed for discrimination and calibration; the better-performing model was then adjusted to the local data and its clinical utility was examined via decision-curve analysis. A local six-predictor model was developed and internally validated via bootstrappaing. Reporting followed TRIPOD and STROBE guidelines. Results: Of 425 treated and resected patients, 85 achieved pCR (20.0%). The pCR yield differed markedly by regimen, from 27.9% with total neoadjuvant therapy and 22.8% with chemoradiotherapy to 10.3% with short-course radiotherapy. The model of Wang and colleagues separated responders from non-responders only modestly (c-statistic 0.62, 95% confidence interval 0.54\u20130.69), and its predictors\u2019 effects proved nearly twice as strong in our patients (slope 0.57); the model of Tan and colleagues performed worse (c-statistic 0.58). A locally refitted model performed no better (optimism-corrected c-statistic 0.60). Adjusting the best model to the local data brought its risk estimates closer to observed responses but did not sharpen discrimination, and decision-curve analysis showed only a small net benefit over default strategies. Conclusions: Two established clinical models for pCR could only be modestly applied to a contemporary European cohort; the risks they predicted overshot what we observed, and local refitting changed nothing\u2014a low ceiling that lies in the predictors, not their coefficients. A clinical model alone should not be used to identify who is offered organ preservation.<\/jats:p>","DOI":"10.3390\/cancers18152390","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:53:26Z","timestamp":1784901206000},"page":"2390","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting Pathological Complete Response in Rectal Cancer: External Validation of Clinical Models"],"prefix":"10.3390","volume":"18","author":[{"given":"Jes\u00fas Pedro","family":"Paredes Cotor\u00e9","sequence":"first","affiliation":[{"name":"Department of Surgery, University Hospital, School of Medicine, University of Santiago de Compostela (USC)\/Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6132-9641","authenticated-orcid":false,"given":"Fernando","family":"Fern\u00e1ndez L\u00f3pez","sequence":"additional","affiliation":[{"name":"Department of Surgery, University Hospital, School of Medicine, University of Santiago de Compostela (USC)\/Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer","volume":"351","author":"Sauer","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa060829","article-title":"Chemotherapy with preoperative radiotherapy in rectal cancer","volume":"355","author":"Bosset","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): A randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): A multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S1470-2045(10)70172-8","article-title":"Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: A pooled analysis of individual patient data","volume":"11","author":"Maas","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.sla.0000141194.27992.32","article-title":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: Long-term results","volume":"240","author":"Perez","year":"2004","journal-title":"Ann. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/S0140-6736(18)31078-X","article-title":"Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): An international multicentre registry study","volume":"391","author":"Bastiaannet","year":"2018","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1470-2045(15)00467-2","article-title":"Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): A propensity-score matched cohort analysis","volume":"17","author":"Renehan","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.22.00032","article-title":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy","volume":"40","author":"Patil","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00384-025-04809-w","article-title":"Deep learning algorithms for predicting pathological complete response in MRI of rectal cancer patients undergoing neoadjuvant chemoradiotherapy: A systematic review","volume":"40","author":"Jong","year":"2025","journal-title":"Int. J. Colorectal Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7145","DOI":"10.1038\/s41598-022-10974-7","article-title":"Clinical prediction model of pathological response following neoadjuvant chemoradiotherapy for rectal cancer","volume":"12","author":"Shin","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e7251","DOI":"10.1002\/cam4.7251","article-title":"A dynamic nomogram for predicting pathologic complete response to neoadjuvant chemotherapy in locally advanced rectal cancer","volume":"13","author":"Wang","year":"2024","journal-title":"Cancer Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Tan, Y., Fu, D., Li, D., Kong, X., Jiang, K., Chen, L., Yuan, Y., and Ding, K. (2019). Predictors and risk factors of pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer: A population-based analysis. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00497"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Cadili, L., Loree, J.M., Peacock, M., DeVries, K., Ghuman, A., Karimuddin, A.A., Phang, P.T., Raval, M.J., and Brown, C.J. (2025). Pathologic complete response after neoadjuvant therapy for locally advanced rectal cancer in a real-world setting: A population-based study. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1573819"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/bjs.9736","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD statement","volume":"102","author":"Collins","year":"2015","journal-title":"Br. J. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"370","author":"Altman","year":"2007","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00330-017-5026-2","article-title":"Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting","volume":"28","author":"Lambregts","year":"2018","journal-title":"Eur. Radiol."},{"key":"ref_19","first-page":"iv22","article-title":"Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Wyrwicz","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.2010.34.4911","article-title":"Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: Pathologic results of the STAR-01 randomized phase III trial","volume":"29","author":"Aschele","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1200\/JCO.21.01667","article-title":"Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR)","volume":"40","author":"Jin","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1200\/JCO.2016.67.6049","article-title":"Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: A multicenter, randomized, controlled trial (GRECCAR-6)","volume":"34","author":"Lefevre","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C","article-title":"Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations","volume":"73","author":"Mandard","year":"1994","journal-title":"Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1200\/JCO.2013.54.3769","article-title":"Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: Updated results of the CAO\/ARO\/AIO-94 trial","volume":"32","author":"Fokas","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1093\/eurheartj\/ehu207","article-title":"Towards better clinical prediction models: Seven steps for development and an ABCD for validation","volume":"35","author":"Steyerberg","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Van Calster, B., McLernon, D.J., van Smeden, M., Wynants, L., and Steyerberg, E.W. (2019). Calibration: The Achilles heel of predictive analytics. BMC Med., 17.","DOI":"10.1186\/s12916-019-1466-7"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: A novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med. Decis. Mak."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/M14-0698","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): Explanation and elaboration","volume":"162","author":"Moons","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7326\/M18-1376","article-title":"PROBAST: A tool to assess the risk of bias and applicability of prediction model studies","volume":"170","author":"Wolff","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","article-title":"Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years","volume":"30","author":"Sauer","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S2468-1253(17)30074-2","article-title":"A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: A systematic review and meta-analysis","volume":"2","author":"Dossa","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2390\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:00:15Z","timestamp":1784901615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":31,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18152390"],"URL":"https:\/\/doi.org\/10.3390\/cancers18152390","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}